AbbVie to Acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, according to an official definitive agreement announced by both companies. Under the established terms of the transaction, AbbVie will acquire all outstanding shares of Apogee common stock for $135.11 per share in cash. This strategic move directly deepens AbbVie’s multi-decade leadership within the global immunology sector while accelerating its clinical footprint in the highly competitive respiratory space.
The proposed acquisition delivers a highly diversified pipeline of clinical-stage candidates engineered to elevate the standard of care for patients suffering from dermatologic, respiratory, and other related inflammatory diseases. At the core of the acquisition is Apogee’s advanced lead asset, zumilokibart (APG777), a late-stage, subcutaneous, half-life extended monoclonal antibody targeting interleukin-13 (IL-13). The molecule is currently undergoing clinical development for patients diagnosed with moderate-to-severe atopic dermatitis (AD).
In addition to its lead monoclonal antibody, Apogee’s development portfolio contains strategic combinations of novel antibodies built to target multiple validated inflammatory pathways. This includes APG273, a potential best-in-category long-acting combination treatment targeting both IL-13 and thymic stromal lymphopoietin (TSLP) optimized for asthma. The pipeline also features APG333, an anti-TSLP half-life extended monoclonal antibody that has demonstrated a prolonged capacity to suppress relevant type 2 inflammatory biomarkers for up to six months during Phase 1 evaluations.
Clinical Rationale Behind the Decision for AbbVie to Acquire Apogee Therapeutics
Robert A. Michael, chairman and chief executive officer of AbbVie, stated that the corporate decision for AbbVie to Acquire Apogee Therapeutics builds upon their existing leadership and strengthens their capacity to deliver innovative biological medicines to underserved patient populations. The acquired pipeline brings highly differentiated clinical-stage assets with mega-blockbuster peak sales potential across multiple indications. AbbVie intends to leverage its deep scientific expertise and extensive operational infrastructure to rapidly advance these new biological programs through late-stage development.
Clinical data from the Phase 2 trial of zumilokibart demonstrated highly significant results, with roughly two-thirds of treated patients achieving major skin clearance at 16 weeks alongside notable improvements in itch resolution and overall disease control. Furthermore, long-term data collected from the trial supports highly convenient maintenance dosing regimens. Patients could potentially receive injections either quarterly or only twice a year, offering a substantial optimization in convenience compared to currently available standard-of-care treatments.
Transaction Timeline and Financial Projections for AbbVie to Acquire Apogee Therapeutics
The definitive agreement ensuring that AbbVie to Acquire Apogee Therapeutics has received unanimous approval from the boards of directors of both organizations. The transaction is projected to close during the third quarter of 2026, subject to customary closing conditions, regulatory clearances, and the formal approval of Apogee’s shareholders. Investment entities Fairmount Funds Management LLC and Venrock Associates have already entered into formal voting agreements in support of the acquisition. Financially, the transaction is expected to be accretive to AbbVie’s adjusted diluted earnings per share (EPS) starting in the year 2032.
